CD4 Update

RNS Number : 8019R

Omega Diagnostics Group PLC

31 October 2013

 



Omega Diagnostics Group PLC

("Omega" or the "Company")

CD4 Update

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following update on its CD4 technology transfer project.

Further to the update given earlier this month, a number of experiments have been performed to investigate the variability within the production process. By definition, the experiments involved testing a number of variant devices, where each individual variant device incorporated controlled changes to a test parameter. The results from testing samples on these variant devices have enabled a majority of variants to be eliminated from further experimentation. The remaining variants are required to undergo further testing in order to select a single preferred manufacturing protocol.  This protocol will be subject to a three-batch evaluation and the Board remains hopeful of completing the technology transfer by the end of December 2013 in line with revised expectations. Ultimately, the Board remains very confident of a successful technology transfer and will provide a further update in due course.

Contacts:

Omega Diagnostics Group PLC	Tel: [phone]
Andrew Shepherd, Chief Executive	www.omegadiagnostics.com
Kieron Harbinson, Group Finance Director
Jag Grewal, Group Sales and Marketing Director
finnCap Ltd	Tel: [phone]
Geoff Nash/Christopher Raggett (Corporate Finance)
Stephen Norcross/Mia Gardner (Corporate Broking)
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

 

END

 

 

MSCMMBFTMBJJBTJ